It is well known that the innovation model for new antibiotics is broken and that there are very few novel antibiotics in the pipeline. What is less known is that unsustainable production and supply of old antibiotics is becoming a serious global problem that further limits the treatment options for common bacterial infections and is adding to the worldwide crisis of antimicrobial resistance.
In a Commentary in the Lancet Infectious Diseases the implications and possible reasons for the increasing problem with lack of availability of essential antibiotics are discussed by leading experts representing key stakeholder groups including ReAct – Action on Antibiotic Resistance, the European Society of Clinical Microbiology and Infectious Diseases, Global Antibiotic R&D Partnership, the International Society of Antimicrobial Chemotherapy, the British Society for Antimicrobial Chemotherapy and the International Society for Infectious Diseases.
“Shortages and sudden price increases of antibiotics have been reported, indicating a fragile supply system. Consequences might include worse clinical outcome, accelerated resistance development, and increased costs for the individual and society at large”,
says Thomas Tängdén, Medical Director at ReAct.
Leadership missing to keep effective antibiotics on the market
The authors are also discussing ways forward to deal with the problem. They point out that despite many political processes have included a call to keep effective antibiotics on the market, leadership in addressing this challenge is still absent. Formation of a multidisciplinary international taskforce could be a first step.
“Governments must request information from the pharmaceutical industry regarding production units and supply chains. National and international authorities must collaborate to ensure continued production, stock management and distribution of essential antibiotics. This is vital if we want to keep having the benefits of antibiotics as the back bone of all health systems”,
concludes professor Otto Cars, founder of ReAct.
For more information, please contact:
Otto Cars: firstname.lastname@example.org, Phone: +46 (0)708 920203
Thomas Tängdén: email@example.com, Phone: +46 (0)708 370323
More news and opinion
- Innovate4AMR: workshop for 11 finalist teams from 9 countries with WHO in Geneva
- ReAct is looking to recruit expert in antibiotic resistance to our team in Sweden
- The State of Kerala, India, launches the 1st sub-national action plan on AMR
- What’s cooking in the antibiotic pipeline?
- Latin America: One Health workshop for teachers
- Kerala, India: perspective of farmers and use of antibiotics in their aquaculture farms
- Innovate4AMR- Innovate for a world free from the fear of untreatable infections
- Definitions and strategies for continued action in Latin America
- Research project in Vietnam: results indicate very high rates of resistance to most antibiotics
- ReAct Europe keynote speaker at WFPHA side event at WHA
- ReAct Latin America: A workshop to reach commitments
- Book release in Latin America: an arena for reflection, awareness and care about antibiotics
- World health day – the rise and fall of antibiotics?
- Antibiotics in the wastewater from pharmaceutical companies: Where are we at?
- Unavailability of old antibiotics is threatening effective treatment of common bacterial infections
- New expert advisory group for the ReAct Toolbox
- ReAct is looking to recruit new Policy Advisor to our team in Sweden
- ReAct reflections on the Prince Mahidol Award Conference and the IACG Civil Society Engagement Panel
- 4 take-aways from the newly published GLASS report
- 4 needs to address so diagnostics can help contain antibiotic resistance
- ReAct responds to final report from DRIVE-AB
- WHO proposes new sepsis target to guide work and actions on antibiotic resistance
- Costing National Action Plans on AMR: practical suggestions for simplifying the process
- Joint letter to IACG on AMR: a call to increase transparency and civil society involvement